Transiente neonatale Myasthenia gravis

Zusammenfassung

Transiente neonatale Myasthenia gravis wird durch Antikörper ausgelöst, die von der Mutter durch die Plazenta auf den Feten passiv übertragen werden. Die Symptome der Erkrankung entwickeln sich erst Stunden bis Tage nach der Geburt. Die betroffenen Kinder zeigen meist Muskelschwäche in Form von Schluck- und Saugproblemen, leises Schreien, ausdrucksschwache Mimik, in 30 % treten respiratorische Komplikationen auf. Bei schweren Formen tritt bereits pränatal eine Arthrogryposis multiplex congenita auf, die auch zum Tode führen kann. Wir berichten über einen Fall der transienten neonatalen Myasthenie, in dem das Neugeborene am 2. Lebenstag durch die typischen Symptome der Erkrankung auffiel.

Summary

Transient neonatal myasthenia gravis occurs in infants born to mothers with myasthenia gravis by passive transfer of antibodies via the placenta. The onset of symptoms occurs within hours up to days after birth. The affected newborns have muscle weakness, swallowing and sucking difficulties, week cry, facial pare-sis, in 30 % respiratory insufficiency. In severe causes of the neonatal myasthenia gravis the children have prenatal arthrogryposis multiplex congenita leading to fetal paralysis or death. We report on a patient with transient neonatal myasthenia gravis who presented with typical symptoms on the second day of life.

Schlüsselwörter

Transiente neonatale Myasthenia gravis - Acetylcholinrezeptor-Antikörper - Acetylcholin -esterase-Inhibitoren - intravenöse Immunglobuline - Arthrogryposis multiplex congenita

Keywords

Transient neonatal myasthenia gravis - acetylcholine receptor antibody - choline esterase inhibiting drugs - intravenous immunoglobulin - arthrogryposis multiplex congenita

• Literatur

• 1 Ahlsten G, Lefvert AK, Osterman PO. et al. Follow-up study of muscle function in children of mothers with myasthenia gravis during pregnancy. J Child Neurol 1992; 7: 264-269.
• 2 Bassan H, Muhlbaur B, Tome A, Spirer Z. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr Neurol 1998; 8: 181-183.
• 3 Behin A, Maye M, Kassis-Makhoul B. et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 2008; 18: 443-446.
• 4 Bezakova G, Ruegg MA. New insights into the roles of agrin. Nat Rev Mol Cell Biol 2003; 4: 295-308.
• 5 Dinger J, Prager B. Arthrogryposis multiplex in a newborn of a myasthenic mother-case report and literature. Neuromuscul Disord 1993; 3: 335-339.
• 6 Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; 1: CD002277.
• 7 Licht C, Model P, Kribs A. et al. Transient neonatal myasthenia gravis. Nervenarzt 2002; 73: 774-778.
• 8 Lindstrom J. Autoimmune diseases involving nicotinic receptors. J Neurobiol 2002; 53: 656-665.
• 9 Lindstrom J. “Seronegative” myasthenia gravis is no longer seronegative. Brain 2008; 131: 1684-1685.
• 10 Namba T, Brown SB, Grob D. Neonatal myasthenia gravis: report of two cases and review of the literature. Pediatrics 1970; 45: 488-504.
• 11 Papazian O. Transient neonatal myasthenia gravis. J Child Neurol 1992; 7: 135-141.
• 12 Tellez-Zenteno JF, Hernandez-Ronquillo L, Salinas V, Estanol B. Myasthenia gravis and pregnancy: clinical implifications and neonatal outcome. BMC Musculoskeletal Disord 2004; 5: 42.
• 13 Vincent A, McConville J, Farrugia ME. et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003; 998: 324-335.
• 14 Williams S, Ryan C, Jacobson C. Agrin and neuregulin, expanding roles and implications for therapeutics. 2008; 26: 187-201.